July 24th 2024
Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.
ADC Gets FDA Fast Track Designation for Platinum-Resistant Recurrent Ovarian Cancer
January 15th 2024RC88, a mesothelin-targeting antibody-drug conjugate, was granted a fast track designation from the FDA for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.